bcl2 monoclonal antibody  (Proteintech)

Journal: BMC Cancer

Article Title: Comparative study of clinical features, pathology, and immunophenotype between HIV-related cutaneous and visceral Kaposi’s sarcoma

doi: 10.1186/s12885-026-15910-w

Figure Lengend Snippet: Immunohistochemical Features. The left panel shows the cutaneous group, specifically from the shoulder skin, and the right panel shows the visceral group, specifically from an inguinal lymph node. Both panels display the immunohistochemical expression of PD-1, PD-L1, CyclinD1, RB, and BCL-2. Among these, PD-1 showed positivity in lymphocytes within the tumor stroma; PD-L1 showed membrane positivity in tumor cells; CyclinD1 and RB showed nuclear positivity; and BCL-2 showed cytoplasmic positivity

Article Snippet: Sections were incubated with rabbit anti-human antibodies against CyclinD1 (SP4), Rb (13A10), BCL-2 (124), P53 (BP-53-12), PD-1 ((2E5), PD-L1 (ZR3), Ki-67 (MIB-1), and, CD34 (QBEnd10) (from Gene Tech, Shanghai, China), HHV8 (13B10) (from zsbio, Beijing, China) for 25 min at room temperature.

Techniques: Immunohistochemical staining, Expressing, Membrane

Journal: bioRxiv

Article Title: Confirmatory evidence that miR-15a and miR-16 regulate BCL2 at the post-transcriptional level

doi: 10.64898/2026.03.02.708996

Figure Lengend Snippet: (A) Relative expression of miR-16-5p measured by RT-qPCR in MEG-01 wild-type (WT) cells transfected with miR-15a or miR-16-1 mimics, corresponding antisense oligonucleotides (AS), or their combinations. Data represent three independent experiments. **** p < 0.001. (B) Relative BCL2 mRNA expression in the same experimental conditions, determined by RT-qPCR using the 2^−ΔCt formula and actin as the reference gene. (C) Semi-quantitative RT-PCR analysis of BCL2 mRNA levels in MEG-01 cells under the indicated conditions, normalized to actin expression. (D) Western blot analysis of BCL2 protein expression in MEG-01 cells, with GAPDH used as a loading control.

Article Snippet: Membranes were blocked and incubated with a mouse monoclonal anti-BCL2 antibody (Santa Cruz Biotechnology) overnight at 4°C.

Techniques: Expressing, Quantitative RT-PCR, Transfection, Western Blot, Control

Journal: Cancer Cell International

Article Title: Silencing Uracil-DNA glycosylase inhibits colorectal cancer progression

doi: 10.1186/s12935-025-04089-y

Figure Lengend Snippet: UNG activated several signaling pathways in CRC cells. Western blot was performed to detect the levels of mTOR, p-mTOR, p70 S6K, p-P70 S6K, AKT, p-AKT, AMPK, p-AMPK, ERK, p-ERK, Bax, Bcl2, cleavages of caspase-9, and caspase-3 in UNG-knockdown CRC cells. Fold changes (Fc) are shown below the bars

Article Snippet: The membranes were incubated overnight at 4 °C with the following primary antibodies: UNG, P70 S6K, p-P70 S6K(S424) (1:1000, Bioworld), β-actin (1:1000, Abcam), cleaved caspase-3, AMPKα1/AMPKα2, p-AMPKα1(Thr183)/AMPKα2(Thr172) (1:1000, Beyotime), BAX, BCL2, AKT1/2/3, mTOR, and p-mTOR (Ser2448) (1:1000; BOSTER), cleaved caspase-9, p-AKT(Ser473), ERK1/2, and p-ERK1/2(Thr202/Tyr204)/(Thr185/Tyr187) (1:1000; ZEN BIO), and GAPDH (1:1000; Proteintech).

Techniques: Protein-Protein interactions, Western Blot, Knockdown